| Status: Excluded due to NICE appraisal | ||
Product meets AWMSG exclusion due to NICE appraisal TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
||
Medicine details |
||
| Medicine name | rituximab (MabThera®) | |
| Formulation | concentrate for solution for infusion | |
| Reference number | 262 | |
| Indication |
|
|
| Company | Roche Products Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | N/A | |
| Status | Excluded due to NICE appraisal | |
| Date of issue | 12/11/2008 | |
| NICE guidance | TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
|